Highlights

  • Second quarter 2026 revenue rose 2.6% to $36.9 million, with GAAP net income of $3.2 million, or $0.15 diluted.
  • Patient Services revenue grew 15.2% to $24.8 million, while Device Solutions revenue fell 16.1% to $12.1 million.
  • Gross margin widened to 58.0% from 55.2%, and operating income rose to $4.2 million from $3.8 million.
  • A new $20.0 million repurchase program, approved May 12, 2026, runs from July 1, 2026 through June 30, 2028.

InfuSystem Holdings (NYSE American:INFU) shares were trading near their 52-week high at USD 13.95 on October 21, 2026, down 1.97%. The infusion services provider approved a new repurchase program in May and filed its quarterly report for the period ended June 30, 2026 on August 4, showing higher profit on slightly higher revenue.

Headquartered in Rochester Hills, Michigan, and a Delaware corporation, InfuSystem describes itself as a national healthcare service provider that facilitates outpatient care for durable medical equipment manufacturers and healthcare providers, serving hospitals, oncology practices and ambulatory surgery centers. It operates from seven locations in the United States and Canada. It reports two segments: Patient Services, led by its oncology business and also covering pain management and wound care, and Device Solutions, which sells and rents infusion pumps and provides biomedical recertification and repair. Its fiscal year ends December 31.

Profit Up on Patient Services Growth, Device Solutions Down

Net revenue for the second quarter of 2026 was $36.9 million, up $0.9 million from $36.0 million. Gross profit rose 7.7% to $21.4 million. GAAP net income was $3.2 million, against $2.6 million, and diluted earnings per share were $0.15 versus $0.12. The effective tax rate was 17%, against 25%.

Patient Services did the lifting. Its revenue rose $3.3 million, with oncology up $1.2 million, or 6.4%, and wound care up $2.1 million, or 154%. The wound care gain included compression devices from two new supplier relationships that launched in the third quarter of 2025 and the first quarter of 2026. Because wound care carries lower margins, Patient Services gross margin slipped 2.4 points to 61.8%, and the company also cited higher pump maintenance costs.

Device Solutions moved the other way. Revenue fell $2.3 million, with biomedical services down $1.8 million and equipment sales down $1.0 million. Of the biomedical decline, $1.6 million reflected a reduced volume and service level on a GE Healthcare contract restructured in the third quarter of 2025. Segment gross margin nonetheless rose to 50.2%, because contract expenses fell by more than the revenue did. General and administrative expenses rose 7.2% to $14.1 million.

For the first half, revenue of $70.6 million was essentially flat, while net income rose to $4.2 million from $2.3 million, or $0.20 per diluted share versus $0.11.

Liquidity, Debt and Share Repurchases

Cash and cash equivalents were $964 thousand at June 30, 2026, with $20.8 million drawn on its $75.0 million revolving facility and $54.2 million of availability, for total liquidity of $55.2 million. The company said it complied with all covenants under its credit agreement. Operating cash flow was $7.7 million in the first half, down from $8.8 million, as accounts receivable rose $5.7 million because of the revenue mix shift toward Patient Services, which collects more slowly.

The company spent $4.4 million repurchasing stock in the first half. Under its previous authorization it had bought back about $15.3 million, or 1,998,735 shares, before that program expired on June 30, 2026. No shares had been repurchased under the new program as of June 30. The filing also notes a first-half migration to a new ERP system that changed internal controls over financial reporting, with no adverse effect expected.

Outlook and Capital Plans

The quarterly report contains no numerical revenue or earnings guidance. Management said it believes it has adequate liquidity for at least the next year, while cautioning that it may need debt or equity markets if unforeseen costs or opportunities arise. The new $20.0 million program obligates it to buy no shares, depends on market conditions and covenant compliance, and can be suspended or ended at any time. The company also says it sees opportunities to acquire smaller regional providers and to expand its payer network. These are company intentions, not completed events.